HK Stocks Update | XUANZHUBIO-B (02575) Rises by 30% Following ESMO Announcement on Phase III Clinical Data for Palbociclib in Breast Cancer

Stock News

Oct 22

XUANZHUBIO-B (02575) continued to gain momentum in the afternoon trading session, peaking at HK$59.85, representing a staggering increase of over 415% from its IPO price of HK$11.6. As of the latest update, the stock is up by 29.67%, priced at HK$59, with a trading volume of HK$183 million. The surge comes after XUANZHUBIO announced it presented Phase III interim analysis results from the BRIGHT-3 study, investigating the combination of palbociclib with letrozole or anastrozole in HR+/HER2- advanced breast cancer. This presentation took place on October 20 at the European Society for Medical Oncology (ESMO) 2025 annual meeting in Germany. The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted at 58 centers across China, aiming to evaluate the efficacy and safety of palbociclib in combination with aromatase inhibitors as first-line treatment for HR+/HER2- advanced breast cancer. Based on the interim data from BRIGHT-3, the National Medical Products Administration of China officially accepted the new drug application for the use of palbociclib in combination with aromatase inhibitors on May 14.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1100345101"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100345101\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100345101?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 14:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100345101","market":"sh","top_or_hot":-1,"title":"HK Stocks Update | XUANZHUBIO-B (02575) Rises by 30% Following ESMO Announcement on Phase III Clinical Data for Palbociclib in Breast Cancer","media":"Stock News","content":"<p>XUANZHUBIO-B (02575) continued to gain momentum in the afternoon trading session, peaking at HK$59.85, representing a staggering increase of over 415% from its IPO price of HK$11.6. As of the latest update, the stock is up by 29.67%, priced at HK$59, with a trading volume of HK$183 million. The surge comes after XUANZHUBIO announced it presented Phase III interim analysis results from the BRIGHT-3 study, investigating the combination of palbociclib with letrozole or anastrozole in HR+/HER2- advanced breast cancer. This presentation took place on October 20 at the European Society for Medical Oncology (ESMO) 2025 annual meeting in Germany. The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted at 58 centers across China, aiming to evaluate the efficacy and safety of palbociclib in combination with aromatase inhibitors as first-line treatment for HR+/HER2- advanced breast cancer. Based on the interim data from BRIGHT-3, the National Medical Products Administration of China officially accepted the new drug application for the use of palbociclib in combination with aromatase inhibitors on May 14.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stocks Update | XUANZHUBIO-B (02575) Rises by 30% Following ESMO Announcement on Phase III Clinical Data for Palbociclib in Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stocks Update | XUANZHUBIO-B (02575) Rises by 30% Following ESMO Announcement on Phase III Clinical Data for Palbociclib in Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-22 14:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XUANZHUBIO-B (02575) continued to gain momentum in the afternoon trading session, peaking at HK$59.85, representing a staggering increase of over 415% from its IPO price of HK$11.6. As of the latest update, the stock is up by 29.67%, priced at HK$59, with a trading volume of HK$183 million. The surge comes after XUANZHUBIO announced it presented Phase III interim analysis results from the BRIGHT-3 study, investigating the combination of palbociclib with letrozole or anastrozole in HR+/HER2- advanced breast cancer. This presentation took place on October 20 at the European Society for Medical Oncology (ESMO) 2025 annual meeting in Germany. The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted at 58 centers across China, aiming to evaluate the efficacy and safety of palbociclib in combination with aromatase inhibitors as first-line treatment for HR+/HER2- advanced breast cancer. Based on the interim data from BRIGHT-3, the National Medical Products Administration of China officially accepted the new drug application for the use of palbociclib in combination with aromatase inhibitors on May 14.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1100345101","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100345101","pubTimestamp":1761115585,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XUANZHUBIO-B (02575) continued to gain momentum in the afternoon trading session, peaking at HK$59.85, representing a staggering increase of over 415% from its IPO price of HK$11.6. As of the latest...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B","III":"信息服务","BK4134":"信息科技咨询与其它服务"},"translate_title":"港股动态|ESMO公布Palbociclib治疗乳腺癌III期临床数据后轩竹生物-B(02575)涨30%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1,"III":1},"content_text":"XUANZHUBIO-B (02575) continued to gain momentum in the afternoon trading session, peaking at HK$59.85, representing a staggering increase of over 415% from its IPO price of HK$11.6. As of the latest update, the stock is up by 29.67%, priced at HK$59, with a trading volume of HK$183 million. The surge comes after XUANZHUBIO announced it presented Phase III interim analysis results from the BRIGHT-3 study, investigating the combination of palbociclib with letrozole or anastrozole in HR+/HER2- advanced breast cancer. This presentation took place on October 20 at the European Society for Medical Oncology (ESMO) 2025 annual meeting in Germany. The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted at 58 centers across China, aiming to evaluate the efficacy and safety of palbociclib in combination with aromatase inhibitors as first-line treatment for HR+/HER2- advanced breast cancer. Based on the interim data from BRIGHT-3, the National Medical Products Administration of China officially accepted the new drug application for the use of palbociclib in combination with aromatase inhibitors on May 14.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}